Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620149 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1HPGDSMN1; SMN2KDM4EPDGFRB | |
| SCHEMBL1366483 | 0.82 | PDGFRB (0.57) | ALDH1A1HPGDSMN1; SMN2KDM4EPDGFRB | |
| SCHEMBL1367379 | 0.79 | PDGFRB (0.58) | ALDH1A1HPGDKDM4EPDGFRBXBP1 | |
| SCHEMBL6649736 | 0.77 | TYMS (0.56) | ALDH1A1HPGDSMN1; SMN2KDM4EXBP1 | |
| SCHEMBL16509138 | 0.76 | CHEK1 (0.46) | ALDH1A1HPGDSMN1; SMN2KDM4EEGFR | |
| SCHEMBL13539588 | 0.74 | POLB (0.47) | ALDH1A1HPGDSMN1; SMN2KDM4EXBP1 | |
| SCHEMBL18623608 | 0.74 | LMNA (0.69) | ALDH1A1SMN1; SMN2KDM4EPOLBLMNA | |
| SCHEMBL6651272 | 0.73 | TYMS (0.47) | ALDH1A1HPGDSMN1; SMN2KDM4EXBP1 | |
| SCHEMBL311846 | 0.73 | ALDH1A1 (0.49) | ALDH1A1HPGDSMN1; SMN2KDM4EXBP1 | |
| SCHEMBL13915414 | 0.73 | SMN1; SMN2 (0.46) | ALDH1A1HPGDSMN1; SMN2PDGFRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-17 | — | — | US | disclosed |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-09 | — | — | US | disclosed |
| EP-2310014-B1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | UNIV HOLY GHOST DUQUESNE (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-01-16 | — | — | US | disclosed |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-11-05 | — | — | US | disclosed |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-09-17 | — | — | US | disclosed |
| US-9987283-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-05-10 | — | — | US | disclosed |
| US-9802955-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-08-31 | — | — | US | disclosed |
| US-20150252053-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2015-09-10 | — | — | US | disclosed |
| US-20150232477-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2015-08-20 | — | — | US | disclosed |
| US-9056869-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-16 | — | — | US | disclosed |
| US-9045489-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2013-04-18 | — | — | US | disclosed |
| US-8309564-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2011-12-01 | — | — | US | disclosed |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | GANGJEE ALEEM (US) | 2011-11-24 | — | — | US | disclosed |
| US-7982035-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | ALDH1A1 1890/4885HPGD 1154/4885SMN1; SMN2 4441/4885 |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | PLK1, AURKC, TOP1 | ALDH1A1 2557/4885HPGD 1781/4885SMN1; SMN2 2226/4885 |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | ALDH1A1 1890/4885HPGD 1154/4885SMN1; SMN2 4441/4885 |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | PLK1, AURKC, TOP1 | ALDH1A1 2557/4885HPGD 1781/4885SMN1; SMN2 2226/4885 |
| US-20150252053-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | ALDH1A1 1890/4885HPGD 1154/4885SMN1; SMN2 4441/4885 |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | ABCG2, ABCC1, ABCB1 | ALDH1A1 1886/4885HPGD 1180/4885SMN1; SMN2 4461/4885 |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | ALDH1A1 1890/4885HPGD 1154/4885SMN1; SMN2 4441/4885 |
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCB1, ABCG2 | ALDH1A1 2007/4885HPGD 1901/4885SMN1; SMN2 4266/4885 |
| US-20150232477-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCC1, ABCG2, TP53 | ALDH1A1 2399/4885HPGD 1741/4885SMN1; SMN2 4366/4885 |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCG2, TP53 | ALDH1A1 2399/4885HPGD 1741/4885SMN1; SMN2 4366/4885 |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | ALDH1A1 1890/4885HPGD 1154/4885SMN1; SMN2 4441/4885 |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCC1, ABCG2, TP53 | ALDH1A1 2399/4885HPGD 1741/4885SMN1; SMN2 4366/4885 |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | ABCG2, ABCC1, ABCB1 | ALDH1A1 1886/4885HPGD 1180/4885SMN1; SMN2 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.